Enanta Pharmaceuticals Inc (NASDAQ:ENTA) shares reached a new 52-week high on Tuesday . The stock traded as high as $62.67 and last traded at $60.98, with a volume of 75000 shares traded. The stock had previously closed at $60.27.

ENTA has been the topic of several analyst reports. Royal Bank of Canada lifted their target price on shares of Enanta Pharmaceuticals from $54.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 21st. TheStreet raised shares of Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Wednesday, December 13th. JMP Securities lifted their target price on shares of Enanta Pharmaceuticals from $40.00 to $53.00 in a research report on Wednesday, October 4th. Finally, Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Four equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $45.25.

The company has a market cap of $1,200.35, a PE ratio of 74.75 and a beta of 0.64.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share for the quarter, missing the consensus estimate of $2.13 by ($0.27). The firm had revenue of $75.93 million during the quarter, compared to analysts’ expectations of $73.80 million. Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The business’s revenue was up 491.3% on a year-over-year basis. During the same period last year, the business earned ($0.09) earnings per share. sell-side analysts predict that Enanta Pharmaceuticals Inc will post -1.57 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC grew its position in Enanta Pharmaceuticals by 5.8% during the second quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in Enanta Pharmaceuticals by 62.9% during the second quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,702 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Enanta Pharmaceuticals during the third quarter valued at approximately $220,000. Hartland & Co. LLC purchased a new position in Enanta Pharmaceuticals during the third quarter valued at approximately $237,000. Finally, Municipal Employees Retirement System of Michigan grew its position in Enanta Pharmaceuticals by 63.7% during the third quarter. Municipal Employees Retirement System of Michigan now owns 5,370 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 2,090 shares in the last quarter. 66.83% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Enanta Pharmaceuticals (ENTA) Hits New 12-Month High at $62.67” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/18/enanta-pharmaceuticals-enta-hits-new-12-month-high-at-62-67.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.